	US 12,076,340 B2
	Use of trientine to deliver copper to ischemic tissue
Yujian James Kang, Sichuan (CN)
Assigned to INNOLIFE CO., LTD., Sichuan (CN)
Filed by INNOLIFE CO., LTD., Sichuan (CN)
Filed on May 10, 2021, as Appl. No. 17/316,577.
Application 17/316,577 is a continuation of application No. 15/762,484, granted, now 11,033,579, previously published as PCT/CN2016/099852, filed on Sep. 23, 2016.
Claims priority of application No. PCT/CN2015/090528 (WO), filed on Sep. 24, 2015.
Prior Publication US 2021/0379102 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/34 (2006.01); A61K 31/132 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01)

CPC A61K 33/34 (2013.01) [A61K 31/132 (2013.01); A61P 9/00 (2018.01); A61P 9/10 (2018.01)]

19 Claims

1. A method of treating cardiac hypertrophy in an individual in need thereof, comprising administering to the individual a composition comprising an effective amount of a copper chelating tetramine, and wherein the composition further comprises a copper ion.